These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15157565)

  • 21. Sepsis and those who are "weak of heart".
    van Kimmenade RR; Bajwa E; Januzzi JL
    Crit Care Med; 2008 Nov; 36(11):3108-9. PubMed ID: 18941317
    [No Abstract]   [Full Text] [Related]  

  • 22. Biomarkers in heart failure.
    Braunwald E
    N Engl J Med; 2008 May; 358(20):2148-59. PubMed ID: 18480207
    [No Abstract]   [Full Text] [Related]  

  • 23. [Natriuretic peptides in heart failure].
    Emdin M; Poletti R; Giannoni A; Mazzei MG; Mammini C; Gabutti A; Agazio A; Caprioli R; Passino C
    G Ital Nefrol; 2006; 23 Suppl 34():S32-7. PubMed ID: 16633992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular and metabolic effects of natriuretic peptides.
    Moro C; Berlan M
    Fundam Clin Pharmacol; 2006 Feb; 20(1):41-9. PubMed ID: 16448393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natriuretic peptides and remodeling in heart failure.
    Burnett JC
    Heart Fail Clin; 2005 Apr; 1(1):129-39. PubMed ID: 17386839
    [No Abstract]   [Full Text] [Related]  

  • 26. Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy.
    Baibars M; Ibrahim A; Fang JC; Sipahi I
    Future Cardiol; 2010 Nov; 6(6):743-7. PubMed ID: 21142628
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D
    Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence.
    Dhar S; Pressman GS; Subramanian S; Kaul S; Gollamudi S; Bloom EJ; Figueredo VM
    Postgrad Med J; 2009 Jun; 85(1004):299-302. PubMed ID: 19528304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of natriuretic peptides in cardioprotection.
    Nishikimi T; Maeda N; Matsuoka H
    Cardiovasc Res; 2006 Feb; 69(2):318-28. PubMed ID: 16289003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the natriuretic peptides.
    Gantzer ML
    MLO Med Lab Obs; 2005 May; 37(5):24, 26-8. PubMed ID: 15960191
    [No Abstract]   [Full Text] [Related]  

  • 32. Towards defining heart failure in adults with congenital heart disease.
    Bolger AP; Gatzoulis MA
    Int J Cardiol; 2004 Dec; 97 Suppl 1():15-23. PubMed ID: 15590075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What do vasoactive peptides tell about the heart?].
    Uusimaa P
    Duodecim; 1998; 22(114):2281, 2283-4. PubMed ID: 11757087
    [No Abstract]   [Full Text] [Related]  

  • 34. [Primary diagnosis of heart failure in ambulatory and hospitalized patients].
    Störk S; Frantz S; Bauersachs J; Ertl G; Angermann CE
    Dtsch Med Wochenschr; 2008 Mar; 133(13):636-41. PubMed ID: 18351507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure.
    Potapov EV; Hennig F; Wagner FD; Volk HD; Sodian R; Hausmann H; Lehmkuhl HB; Hetzer R
    Eur J Cardiothorac Surg; 2005 May; 27(5):899-905. PubMed ID: 15848333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurohumoral pathways in heart failure with preserved systolic function.
    Hogg K; McMurray J
    Prog Cardiovasc Dis; 2005; 47(6):357-66. PubMed ID: 16115515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asymmetrical myocardial expression of natriuretic peptides in pacing-induced heart failure.
    Del Ry S; Cabiati M; Lionetti V; Simioniuc A; Caselli C; Prescimone T; Emdin M; Giannessi D
    Peptides; 2009 Sep; 30(9):1710-3. PubMed ID: 19540894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B-type natriuretic peptide: time to incorporate natriuretic peptides in our practice.
    Daniels LB; Maisel A
    J Cardiovasc Med (Hagerstown); 2006 Jun; 7(6):414-5. PubMed ID: 16721203
    [No Abstract]   [Full Text] [Related]  

  • 39. Myocardial substrate metabolism in the normal and failing heart.
    Stanley WC; Recchia FA; Lopaschuk GD
    Physiol Rev; 2005 Jul; 85(3):1093-129. PubMed ID: 15987803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure.
    Perna ER; Macin SM; Cimbaro Canella JP; Szyszko A; Franciosi V; Vargas Morales W; Bayol AP; Kriskovich JO; Medina F; Gonzalez Arjol B; Brizuela M
    J Heart Lung Transplant; 2006 Oct; 25(10):1230-40. PubMed ID: 17045936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.